Influenza Vaccine Reduces Risk of Adverse Cardiovascular Events in High-Risk Patients
Am Fam Physician. 2014 Feb 1;89(3):224-225.
Does the influenza vaccine lower the risk of major adverse cardiovascular events in adults with coronary disease?
This meta-analysis found that the influenza vaccine is associated with a significantly lower risk of major adverse cardiovascular events in adults with coronary disease. The benefit of influenza vaccination is strongest in adults with a history of recent acute coronary syndrome within the previous six months (number needed to treat [NNT] = 8). (Level of Evidence = 1a)
These investigators searched multiple sources, including Medline, Embase, the Cochrane Register, reference lists of eligible articles, clinicaltrials.gov, and conference abstracts without language restrictions for all published and unpublished randomized clinical trials comparing influenza vaccination with placebo or standard care. Two investigators independently reviewed potential studies for inclusion and methodologic quality using standard scoring tools. Disagreements were resolved by consensus. Six randomized controlled trials met inclusion criteria for the final meta-analysis. These trials (N = 6,735) compared influenza vaccine with placebo or control for a mean duration of 7.9 months. The primary outcome measured was a composite of major adverse cardiovascular events, including cardiovascular death or hospitalization for myocardial infarction, unstable angina, stroke, heart failure, or urgent coronary bypass surgery.
In the analysis of the six included trials, significantly fewer vaccinated patients developed a major adverse cardiovascular event compared with those in the placebo or control groups (2.9% vs. 4.7%, respectively; NNT = 58; 95% confidence interval, 38 to 124). The benefit of vaccination was strongest in the subset of patients with a history of recent acute coronary syndrome within the previous six months (10.25% with vaccine vs. 23.1% with placebo or control; NNT = 8; 95% confidence interval, 6 to 13). There was, however, no significant difference in all-cause mortality between the vaccinated and placebo or control patient groups. Formal statistical analyses found no evidence of significant heterogeneity among the trials or publication bias.
Study design: Meta-analysis (randomized controlled trials)
Funding source: Government
Setting: Various (meta-analysis)
Reference: Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013; 310( 16): 1711– 1720.
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for "Poem of the Week" or go to http://goo.gl/3niWXb.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 1, 2017
Access the latest issue of American Family Physician